> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Feds Looking Into Janssen False Claims Act Allegations
- URL: https://www.fdaweb.com/feds-looking-into-janssen-false-claims-act-allegations/
- Published: 2017-05-09T12:00:00.000Z
- Updated: 2026-09-14T22:22:28.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138649

The Justice Department has opened an investigation into management and advisory services provided by Johnson & Johnson’s Janssen unit to rheumatology and gastroenterology practices that bought its Remicade (infliximab) and Simponi Aria (golimumab) arthritis drugs. Reuters reports that the company also indicated in a quarterly filing that the U.S. Attorney in Massachusetts is seeking documents broadly relating to drug co-payment support programs for Simponi, the hepatitis C drug Olysiotm (simeprevir) , and the Crohn’s disease drug Stelara (ustekinumab). The U.S. Attorney’s subpoena also seeks documents relating to average manufacturer price and best price reporting to the Center for Medicare and Medicaid services related to those products, as well as rebate payments to state Medicaid agencies, Johnson & Johnson said.